Stage IB-IIIA Non-small Cell Lung CarcinomaPhase 3ADAURANCT02511106
AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.
A Phase 3 study testing AZD9291 80 mg/40 mg and Open-label AZD9291 80 mg/40 mg in people with Stage IB-IIIA Non-small Cell Lung Carcinoma, run by AstraZeneca at 238 sites in 25 countries.
Trial summary
To assess the efficacy and safety of AZD9291 versus Placebo, in patients with Epidermal Growth Factor Receptor Mutation Positive stage IB-IIIA non-small cell lung carcinoma, following complete tumour resection with or without adjuvant chemotherapy Read more about this study
- Who is it for?
- Ages 18 to 130 years
- Conditions the study is for
- Stage IB-IIIA Non-small Cell Lung Carcinoma
- What is being tested?
- AZD9291 80 mg/40 mg and Open-label AZD9291 80 mg/40 mg
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 682 participants
- Where
- 238 sitesin 25 countries
- Study dates
- 21 Oct 2015to 31 Jan 2029
- Phase
- Phase 3
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 130 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male or female, aged at least 18 years.
- Histologically confirmed diagnosis of primary non small lung cancer (NSCLC) on predominantly non-squamous histology
- MRI or CT scan of the brain must be done prior to surgery as it is considered standard of care.
- Patients must be classified post-operatively as Stage IB, II or IIIA on the basis of pathologic criteria.
- Confirmation by the central laboratory that the tumour harbours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR mutations including T790M.
- Complete surgical resection of the primary NSCLC is mandatory. All gross disease must have been removed at the end of surgery. All surgical margins of resection must be negative for tumour.
Show all 9Show fewer
- Complete recovery from surgery and standard post-operative therapy (if applicable) at the time of randomization.
- World Health Organization Performance Status of 0 to 1.
- Female patients should be using adequate contraceptive measures, should not be breast feeding, and must have a negative pregnancy test prior to first dose of study drug; or female patients must have an evidence of non-child-bearing potential.
Who cannot join
- Treatment with any of the following:
- Pre-operative or post-operative or planned radiation therapy for the current lung cancer
- Pre-operative (neo-adjuvant) platinum based or other chemotherapy
- Any prior anticancer therapy
- Prior treatment with neoadjuvant or adjuvant EGFR-TKI at any time
- Major surgery (including primary tumour surgery, excluding placement of vascular access) within 4 weeks of the first dose of study drug
Show all 19Show fewer
- Patients currently receiving medications or herbal supplements known to be potent inducers of cytochrome P450 (CYP) 3A4
- Treatment with an investigational drug within five half-lives of the compound or any of its related material.
- Patients who have had only segmentectomies or wedge resections
- History of other malignancies, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer, or other solid tumours curatively treated with no evidence of disease for > 5 years following the end of treatment.
- Any unresolved toxicities from prior therapy greater than CTCAE Grade 1 at the time of starting study treatment with the exception of alopecia and Grade 2, prior platinum-therapy related neuropathy.
- Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses; or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV).
- Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of AZD9291.
- Any of the following cardiac criteria:
- Mean resting corrected QT interval (QTc) >470 msec, obtained from 3 ECGs, using the screening clinic ECG machine-derived QTc value.
- Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG.
- Any factors that increase the risk of QTc prolongation or risk of arrhythmic events, or unexplained sudden death under 40 years of age in first-degree relatives or any concomitant medication known to prolong the QT interval.
- Past medical history of ILD, drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD.
- Inadequate bone marrow reserve or organ function.
Trial locations and contacts
238 sites in 25 countries.
238 sites in 25 countries
China29 sites
Research Site
Beijing, 100029
Research Site
Beijing, 100142
Research Site
Beijing, 100210
Research Site
Beijing, 100730
Research Site
Changchun, 130012
Research Site
Changchun, 130021
Research Site
Dalian, 116027
Research Site
Guangzhou, 510060
Research Site
Guangzhou, 510120
Research Site
Guangzhou, 510180
Research Site
Hangzhou, 310003
Research Site
Hangzhou, 310009
Research Site
Hangzhou, 310022
Research Site
Kunming, 650118
Research Site
Nanjing, 210029
Research Site
Nanning, 530021
Research Site
Shanghai, 200030
Research Site
Shanghai, 200032
Research Site
Shanghai, 200072
Research Site
Shenyang, 110001
Research Site
Suzhou, 215006
Research Site
Tianjin, 300050
Research Site
Tianjin, 300051
Research Site
Tianjin, 300060
Research Site
Ürümqi, 830000
Research Site
Xi'an, 710061
Research Site
Xiamen, 361004
Research Site
Yangzhou, 225001
Research Site
Zhengzhou, 450008
Japan24 sites
Research Site
Bunkyō City, 113-8431
Research Site
Fukuoka, 812-8582
Research Site
Hirakata-shi, 573-1191
Research Site
Hiroshima, 730-8518
Research Site
Hiroshima, 734-8551
Research Site
Kanazawa, 920-8641
Research Site
Kashiwa, 277-8577
Research Site
Kitakyushu-shi, 807-8555
Research Site
Kobe, 650-0047
Research Site
Kurume-shi, 830-0011
Research Site
Matsuyama, 791-0280
Research Site
Nagoya, 453-8511
Research Site
Niigata, 951-8566
Research Site
Osakasayama-shi, 589-8511
Research Site
Sagamihara-shi, 252-0375
Research Site
Sakaishi, 591-8555
Research Site
Sasebo-shi, 857-8511
Research Site
Sendai, 980-0873
Research Site
Shinjuku-ku, 160-0023
Research Site
Sunto-gun, 411-8777
Research Site
Ube-shi, 755-0241
Research Site
Yokohama, 240-8555
Research Site
Yokohama, 241-8515
Research Site
Yonago-shi, 683-8504
United States23 sites
Research Site
Athens, Georgia, 30607
Research Site
Bethesda, Maryland, 20817
Research Site
Brick, New Jersey, 08724
Research Site
Chattanooga, Tennessee, 37404
Research Site
Chicago, Illinois, 60612
Research Site
Elk Grove Village, Illinois, 60007
Research Site
Florham Park, New Jersey, 07932
Research Site
Fort Belvoir, Virginia, 22060
Research Site
Fort Myers, Florida, 33901
Research Site
Grand Junction, Colorado, 81501
Research Site
Honolulu, Hawaii, 96819
Research Site
Los Angeles, California, 90048
Research Site
Mineola, New York, 11501
Research Site
Nashville, Tennessee, 37203
Research Site
New Haven, Connecticut, 06520
Research Site
Norwalk, Connecticut, 06856
Research Site
Pawtucket, Rhode Island, 02860
Research Site
Pembroke Pines, Florida, 33028
Research Site
San Antonio, Texas, 78229
Research Site
Santa Monica, California, 90404
Research Site
Santa Rosa, California, 95403
Research Site
St. Petersburg, Florida, 33705
Research Site
Torrance, California, 90505
Germany16 sites
Research Site
Aachen, 52074
Research Site
Berlin, 12351
Research Site
Berlin, 13125
Research Site
Berlin, 13359
Research Site
Cologne, 51109
Research Site
Coswig, 01640
Research Site
Gauting, 82131
Research Site
Gerlingen, 70839
Research Site
Großhansdorf, 22927
Research Site
Halle, 06120
Research Site
Hamburg, 20251
Research Site
Homburg, 66421
Research Site
Immenhausen, 34376
Research Site
Kassel, 34125
Research Site
Lübeck, 23538
Research Site
Würzburg, 97074
Italy15 sites
Research Site
Bari, 70124
Research Site
Bergamo, 24127
Research Site
Bologna, 40138
Research Site
Cremona, 26100
Research Site
Florence, 50134
Research Site
Lucca, 55100
Research Site
Meldola, 47014
Research Site
Milan, 20132
Research Site
Milan, 20141
Research Site
Milan, 20162
Research Site
Novara, 28100
Research Site
Orbassano, 10043
Research Site
Padova, 35128
Research Site
Parma, 43126
Research Site
Roma, 00152
Russia14 sites
Research Site
Arkhangelsk, 163045
Research Site
Kazan', 420029
Research Site
Moscow, 115478
Research Site
Moscow, 143423
Research Site
Obninsk, 249036
Research Site
Omsk, 644013
Research Site
Pyatigorsk, 357502
Research Site
Rostov-on-Don, 344037
Research Site
Ryazan, 390011
Research Site
Saint Petersburg, 194291
Research Site
Saint Petersburg, 195271
Research Site
Saint Petersburg, 197022
Research Site
Saint Petersburg, 197758
Research Site
Saint Petersburg, 198255
Spain14 sites
Research Site
A Coruña, 15006
Research Site
Barcelona, 08041
Research Site
Donostia / San Sebastian, 20014
Research Site
Elche, 03203
Research Site
Las Palmas de Gran Canaria, 35016
Research Site
Madrid, 08035
Research Site
Madrid, 28007
Research Site
Madrid, 28040
Research Site
Madrid, 28046
Research Site
Majadahonda, 28222
Research Site
Málaga, 29010
Research Site
Valencia, 46010
Research Site
Valencia, 46026
Research Site
Zaragoza, 50009
Brazil11 sites
Research Site
Barretos, 14784-400
Research Site
Cachoeira de Itapemirim, 29308-055
Research Site
Curitiba, 81520-060
Research Site
Florianópolis, 88034-000
Research Site
Fortaleza, 60810-180
Research Site
Lajeado, 95900000
Research Site
Porto Alegre, 90619-900
Research Site
Rio de Janeiro, 22793-080
Research Site
Salvador, 40170-110
Research Site
São José do Rio Preto, 15025-100
Research Site
São Paulo, 01321-001
Taiwan9 sites
Research Site
Changhua, 50006
Research Site
Putzu City, 0613
Research Site
Taichung, 402
Research Site
Taichung, 40705
Research Site
Tainan, 70403
Research Site
Tainan, 73657
Research Site
Taipei, 10002
Research Site
Taipei, 112
Research Site
Taoyuan, 333
South Korea8 sites
Research Site
Cheongju-si, 28644
Research Site
Seoul, 02841
Research Site
Seoul, 05030
Research Site
Seoul, 05505
Research Site
Seoul, 06351
Research Site
Seoul, 07061
Research Site
Suwon, 16247
Research Site
Suwon, 16499
Turkey (Türkiye)8 sites
Research Site
Ankara, 06280
Research Site
Ankara, 6500
Research Site
Bursa, 16059
Research Site
Istanbul, 34069
Research Site
Istanbul, 34093
Research Site
Istanbul, 34098
Research Site
Istanbul, 34722
Research Site
Izmir, 35100
Australia7 sites
Research Site
Bedford Park, 5042
Research Site
Camperdown, 2050
Research Site
Darlinghurst, 2010
Research Site
Heidelberg, 3084
Research Site
Kogarah, 2217
Research Site
Kurralta Park, 5037
Research Site
Woolloongabba, 4102
Israel7 sites
Research Site
Beersheba, 8410101
Research Site
Haifa, 31999
Research Site
Jerusalem, 91120
Research Site
Kfar Saba, 4428164
Research Site
Petah Tikva, 4941492
Research Site
Ramat Gan, 5262000
Research Site
Tel Aviv, 6423906
Poland7 sites
Research Site
Krakow, 31-202
Research Site
Lodz, 90-302
Research Site
Otwock, 05-400
Research Site
Poznan, 60-569
Research Site
Racibórz, 47-400
Research Site
Warsaw, 02-781
Research Site
Wieliszew, 05-135
Romania7 sites
Research Site
Bucharest, 031422
Research Site
Bucharest, 050098
Research Site
Cluj-Napoca, 400015
Research Site
Craiova, 200385
Research Site
Focşani, 620165
Research Site
Iași, 700483
Research Site
Timișoara, 300210
Thailand7 sites
Research Site
Bangkok, 10330
Research Site
Bangkok, 10700
Research Site
Chiang Rai, 57000
Research Site
Khon Kaen, 40002
Research Site
Mueang, 50200
Research Site
Phitsanulok, 65000
Research Site
Songkhla, 90110
Ukraine6 sites
Research Site
Dnipro, 49102
Research Site
Lviv, 79031
Research Site
Sumy, 40022
Research Site
Uzhhorod, 88000
Research Site
Vinnytsia, 21029
Research Site
Zaporizhzhya, 69040
France5 sites
Research Site
Bron, 69677
Research Site
Lille, 59000
Research Site
Limoges, 87042
Research Site
Lyon, 69008
Research Site
Paris, 75020
Hungary5 sites
Research Site
Budapest, 1083
Research Site
Budapest, 1121
Research Site
Deszk, 6772
Research Site
Székesfehérvár, 8000
Research Site
Törökbálint, 2045
Belgium4 sites
Research Site
Brussels, 1090
Research Site
Brussels, 1200
Research Site
Ghent, 9000
Research Site
Kortrijk, 8500
Netherlands4 sites
Research Site
Amsterdam, 1081 HV
Research Site
Arnhem, 6815 AD
Research Site
Hoofddorp, 2134 TM
Research Site
Zwolle, 8025 AB
Hong Kong3 sites
Research Site
Hong Kong, 150001
Research Site
Hong Kong
Research Site
King's Park, 150001
Vietnam3 sites
Research Site
Hanoi, 100000
Research Site
Hanoi, 10000
Research Site
Ho Chi Minh City, 70000
About this study
Official title: A Phase III, Double-blind, Randomized, Placebo-controlled Multi-centre, Study to Assess the Efficacy and Safety of AZD9291 Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy (ADAURA).
To assess the efficacy and safety of AZD9291 versus Placebo, in patients with Epidermal Growth Factor Receptor Mutation Positive stage IB-IIIA non-small cell lung carcinoma, following complete tumour resection with or without adjuvant chemotherapy
Read the detailed description
This is a phase 3 double-blind, randomized, placebo-controlled, study to assess the efficacy and safety of AZD9291 versus placebo in patients with stage IB-IIIA non-small cell lung cancer (NSCLC) with centrally confirmed, most common sensitising EGFR mutations (Ex19Del and L858R) either alone or in combination with other EGFR mutations as confirmed by a central test, who have had complete tumour resection, with or without postoperative adjuvant chemotherapy. Adjuvant chemotherapy should have consisted of a platinum based doublet given for a maximum of 4 cycles.
- Being tested
- AZD9291 80 mg/40 mg, Placebo AZD9291 80 mg/40 mg, Open-label AZD9291 80 mg/40 mg
- Keywords
- Stage IB-IIA-IIIA Non-Small Cell Lung Cancer; EGFRm+; Ex19Del; L858R; AZD9291; Phase III, adjuvant chemotherapy; complete tumour resection; EGFR-TKI
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AZD9291 80 mg/40 mgDrug
The initial dose of AZD9291 80 mg once daily can be reduced to 40 mg once daily.
Placebo AZD9291 80 mg/40 mgDrug
The initial dose of Placebo AZD9291 80 mg once daily can be reduced to 40 mg once daily.
Open-label AZD9291 80 mg/40 mgDrug
Eligible patients will be offered open-label osimertinib upon recurrence and in the absence of intervening systemic anti-cancer therapy.
| Study group | Role | What they receive |
|---|---|---|
| AZD9291 | Experimental | AZD9291 (80 mg or 40 mg orally, once daily), in accordance with the randomization schedule. Receives: Drug: AZD9291 80 mg/40 mg; Drug: Open-label AZD9291 80 mg/40 mg |
| Placebo AZD9291 | Placebo comparator | Matching placebo for AZD9291 (80 mg or 40 mg orally, once daily), in accordance with the randomization schedule. Receives: Drug: Placebo AZD9291 80 mg/40 mg |
What is being measured
The primary outcome is the main question the study is designed to answer.
Assess the Efficacy of AZD9291 Compared to Placebo as Measured by Disease Free Survival (DFS).
Defined as the time from the date of randomization until the date of disease recurrence or death (by any cause in the absence of recurrence).
Measured: Up to approximately 5 years after the first patient is randomized (maximum follow up of 70 months)
Secondary outcomes (7)
Disease Free Survival (DFS) Rate at 2, 3 and 5 Years
Defined as the percentage of patients alive and disease free at 2, 3 and 5 years, respectively, estimated from Kaplan Meier plots of the primary endpoint of DFS.
Measured: Up to approximately 5 years after the first patient is randomized (maximum follow up of 70 months). DFS rate at 2 years (%), 3 years (%) and 5 years (%) are presented.
Overall Survival (OS)
Defined as the time from the date of randomization until date of death due to any cause.
Measured: Up to approximately 7 years after the first patient is randomized (maximum follow up of 86 months)
Overall Survival Rate at 2, 3 and 5 Years
Defined as the percentage of patients alive at 2, 3 and 5 years, respectively, estimated from a Kaplan Meier plot of OS.
Measured: Up to approximately 7 years after the first patient is randomized (maximum follow up of 86 months). OS rate at 2 years (%), 3 years (%) and 5 years (%) are presented.
Patient Health-related Quality of Life and Symptoms (HRQoL) by SF-36v2 Health Survey.
Change from baseline will be calculated for each domain and summary scale at each scheduled post-baseline assessment. The SF-36 includes eight domains: Physical Functioning (PF); Role Limitations-Physical (RP), Vitality (VT), General Health Perceptions (GH), Bodily Pain (BP), Social Function (SF), Role Limitations-Emotional (RE), and Mental Health (MH) and two summary scores: The Physical Component Summary (PCS) and Mental Component Summary (MCS). Final scores for each scale range from 0-100 with higher scores indicating better health.
Measured: Measured by SF-36 Questionnaire at baseline, 12 week, 24 week and then every 24 weeks until study complete, disease recurrence or other discontinuation criteria met, up to 3 years.
Plasma Concentrations of AZD9291
The pharmacokinetics exposure parameters derived from plasma concentrations of AZD9291
Measured: Collected at pre-dose, 0.5-1.5hours and 2-4hours post-dose up to 96 weeks (approximately 24 months)
Plasma Concentrations of AZ5104 Metabolites
The pharmacokinetics exposure parameters derived from plasma concentrations of AZ5104 metabolites
Measured: From date of dosing to week 96 (approximately 24 months)
Plasma Concentrations of AZ7550 Metabolites
The pharmacokinetics exposure parameters derived from plasma concentrations of AZ7550 metabolites
Measured: From date of dosing to week 96 (approximately 24 months)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Jul 2015 (estimated)
- Study start21 Oct 2015
- Primary completion11 Apr 2022
- Study completion31 Jan 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (15)Papers the sponsor has linked to this study.
- Other trials for Stage IB-IIIA Non-small Cell Lung CarcinomaStudies of the same condition, open and under way.
- More trials run by AstraZenecaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 682 participants (actual)
Sponsor and investigators
- Lead sponsor
- AstraZeneca
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02511106
- Sponsor's protocol ID
- D5164C00001
- Other IDs
- 2023-506524-82-00, 2015-000662-65, 2015, 2023
- Acronym
- ADAURA
- Status last verified
- Sep 2026
- First submitted
- 28 Jul 2015
- Last updated
- 11 Sep 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- Individual data sharing
- Yes: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Publications
Herbst RS, Wu YL, Tsuboi M. Osimertinib in EGFR-Mutated Lung Cancer. Reply. N Engl J Med. 2021 Feb 18;384(7):675-676. doi: 10.1056/NEJMc2033951. No abstract available.
PubMed 33596365Wu YL, Majem M, John T, Grohe C, Wang J, Goldman JW, Lu S, Shepherd FA, Wang Q, Kato T, Aokage K, Zhong WZ, Laktionov K, Wu MF, Akewanlop C, Vu HV, Lee KH, Huang X, Armenteros-Monterroso E, Rukazenkov Y, Herbst RS. Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB-IIIA Non-Small Cell Lung Cancer: Exploratory 8-year Overall Survival Landmark Update from the ADAURA Trial [161/175]. J Thorac Oncol. 2026 Sep 13:104179. doi: 10.1016/j.jtho.2026.104179. Online ahead of print.
PubMed 42732874Murat-Onana ML, Ramalingam SS, Janne PA, Gray JE, Ahn MJ, John T, Yatabe Y, Huang X, Rukazenkov Y, Javey M, Brown H, Li-Sucholeiki X. EGFR mutation testing across the osimertinib clinical program. Lung Cancer. 2025 Jun;204:108549. doi: 10.1016/j.lungcan.2025.108549. Epub 2025 Apr 18.
PubMed 40311309Herbst RS, John T, Grohe C, Goldman JW, Kato T, Laktionov K, Bonanno L, Tiseo M, Majem M, Domine M, Ahn MJ, Kowalski DM, Perol M, Sriuranpong V, Ozguroglu M, Bhetariya P, Markovets A, Rukazenkov Y, Muldoon C, Robichaux J, Hartmaier R, Tsuboi M, Wu YL. Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer. Nat Med. 2025 Jun;31(6):1958-1968. doi: 10.1038/s41591-025-03577-y. Epub 2025 Mar 17.
PubMed 40097663Dwyer LJ, Singhal N, Yu B, Kao S. Successful Osimertinib Rechallenge After Relapse Following Adjuvant Osimertinib: A Case Report. J Thorac Oncol. 2024 Apr;19(4):650-652. doi: 10.1016/j.jtho.2024.01.001. Epub 2024 Feb 9.
PubMed 38340108Wu D, Li GF. Improving Report of the ADAURA Trial by Distinguishing Treatment-Related Adverse Events From Treatment-Emergent Adverse Events and Assessing Independence of Censoring in Final Disease-Free Survival Analyses. J Clin Oncol. 2023 Sep 10;41(26):4317-4318. doi: 10.1200/JCO.23.00604. Epub 2023 Jun 30. No abstract available.
PubMed 37390376Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohe C, Wang J, Goldman JW, Lu S, Su WC, de Marinis F, Shepherd FA, Lee KH, Le NT, Dechaphunkul A, Kowalski D, Poole L, Bolanos A, Rukazenkov Y, Wu YL; ADAURA Investigators. Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC. N Engl J Med. 2023 Jul 13;389(2):137-147. doi: 10.1056/NEJMoa2304594. Epub 2023 Jun 4.
PubMed 37272535John T, Grohe C, Goldman JW, Shepherd FA, de Marinis F, Kato T, Wang Q, Su WC, Choi JH, Sriuranpong V, Melotti B, Fidler MJ, Chen J, Albayaty M, Stachowiak M, Taggart S, Wu YL, Tsuboi M, Herbst RS, Majem M. Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial. J Thorac Oncol. 2023 Sep;18(9):1209-1221. doi: 10.1016/j.jtho.2023.05.015. Epub 2023 May 24.
PubMed 37236398Herbst RS, Wu YL, John T, Grohe C, Majem M, Wang J, Kato T, Goldman JW, Laktionov K, Kim SW, Yu CJ, Vu HV, Lu S, Lee KY, Mukhametshina G, Akewanlop C, de Marinis F, Bonanno L, Domine M, Shepherd FA, Urban D, Huang X, Bolanos A, Stachowiak M, Tsuboi M. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. J Clin Oncol. 2023 Apr 1;41(10):1830-1840. doi: 10.1200/JCO.22.02186. Epub 2023 Jan 31.
PubMed 36720083John T, Majem M, Legg D, Goldman J. Current and Future Perspectives of Health-Related Quality of Life in Resectable EGFR-Mutated Non-Small Cell Lung Cancer: A Podcast. Target Oncol. 2023 Jan;18(1):1-8. doi: 10.1007/s11523-022-00927-5. Epub 2022 Dec 19. No abstract available.
PubMed 36534268Majem M, Goldman JW, John T, Grohe C, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Li S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Atagi S, Zeng L, Kulkarni D, Medic N, Tsuboi M, Herbst RS, Wu YL. Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial. Clin Cancer Res. 2022 Jun 1;28(11):2286-2296. doi: 10.1158/1078-0432.CCR-21-3530.
PubMed 35012927Wu YL, John T, Grohe C, Majem M, Goldman JW, Kim SW, Kato T, Laktionov K, Vu HV, Wang Z, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Atasoy A, Herbst RS, Tsuboi M. Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC. J Thorac Oncol. 2022 Mar;17(3):423-433. doi: 10.1016/j.jtho.2021.10.014. Epub 2021 Nov 2.
PubMed 34740861Wu YL, Tsuboi M, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS. A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer. Future Oncol. 2021 Dec 1;17(35):4827-4835. doi: 10.2217/fon-2021-0752. Epub 2021 Nov 1.
PubMed 34723634Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS; ADAURA Investigators. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. N Engl J Med. 2020 Oct 29;383(18):1711-1723. doi: 10.1056/NEJMoa2027071. Epub 2020 Sep 19.
PubMed 32955177Wu YL, Herbst RS, Mann H, Rukazenkov Y, Marotti M, Tsuboi M. ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection. Clin Lung Cancer. 2018 Jul;19(4):e533-e536. doi: 10.1016/j.cllc.2018.04.004. Epub 2018 May 1.
PubMed 29789220